F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer 5 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers 6 in 185 countries, CA Cancer J Clin. nov, vol.68, issue.6, pp.394-424, 2018.

A. Heintz, F. Odicino, P. Maisonneuve, M. A. Quinn, J. L. Benedet et al.,

, Carcinoma of the ovary

, Gynecological Cancer. Int J Gynaecol Obstet, vol.95, issue.1, pp.161-92, 2006.

J. Prat, . Figo-committee-on-gynecologic, and . Oncology, Staging classification for cancer 11 of the ovary, fallopian tube, and peritoneum, Int J Gynaecol Obstet. janv, vol.124, issue.1, pp.1-5, 2014.

I. Vergote, C. G. Tropé, F. Amant, G. B. Kristensen, T. Ehlen et al.,

, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J

. Med, , vol.363, pp.943-53, 2010.

M. Peiretti, V. Zanagnolo, G. D. Aletti, L. Bocciolone, N. Colombo et al., Role 16 of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and 17 tubal cancer: Surgical and oncological outcomes

, Oncol, vol.119, issue.2, pp.259-64, 2010.

, European Society of Gynaecological Oncology. Ovarian Cancer Surgery Guidelines, p.20

, Advanced stage. guidelines.esgo.org, 2016.

S. Kehoe, J. Hook, M. Nankivell, G. C. Jayson, H. Kitchener et al., Primary 12 chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer 13 (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet. 18 juill, vol.14, issue.9990, pp.249-57, 2015.

A. Fagotti, G. Ferrandina, G. Vizzielli, F. Fanfani, V. Gallotta et al., Phase 16 III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in 17 advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis 18 of peri-operative outcome, Eur J Cancer, vol.59, pp.22-33, 2016.

S. M. Eisenkop, R. L. Friedman, and H. J. Wang, Complete cytoreductive surgery is feasible and 20 maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

, Gynecol Oncol. mai, vol.69, issue.2, pp.103-111, 1998.

R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, Survival effect of 23 maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a 24 meta-analysis, J Clin Oncol. 1 mars, vol.20, issue.5, pp.1248-59, 2002.

C. Vermeulen, W. Tadesse, M. Timmermans, R. Kruitwagen, and T. Walsh, Only 2 complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal 3 debulking in advanced ovarian cancer, Eur J Obstet Gynecol Reprod Biol. déc, vol.4, pp.100-105, 2017.

T. Le, K. Williams, M. Senterman, L. Hopkins, W. Faught et al., Omental 6 chemotherapy effects as a prognostic factor in ovarian cancer patients treated with 7 neoadjuvant chemotherapy and delayed primary surgical debulking, Ann Surg Oncol. sept, vol.8, issue.9, pp.2649-53, 2007.

S. M. Sørensen, T. H. Schnack, and C. Høgdall, Impact of residual disease on overall survival 10 in patients with FIGO stage IIIB-IIIC vs. stage IV epithelial ovarian cancer after primary 11 surgery, Acta Obstet Gynecol Scand. 31 août, 2018.

Y. J. Lee, Y. S. Chung, J. Lee, N. E. Kim, S. W. Kim et al., Impact of increased 13 utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: 14 experience from a comprehensive cancer center, Journal of Gynecologic Oncology

, , vol.29, p.23

I. Vergote, F. Amant, G. Kristensen, T. Ehlen, N. S. Reed et al., Primary surgery or 18 neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian 19 cancer, Eur J Cancer. sept, vol.47, issue.3, pp.88-92, 2011.

N. F. Hacker and A. Rao, Surgery for advanced epithelial ovarian cancer, Best Pract Res, vol.21

, Clin Obstet Gynaecol. mai, vol.41, pp.71-87, 2017.

P. G. Rose, J. J. Java, M. A. Morgan, A. A. Secord, J. P. Kesterson et al., Disease 23 Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall 24

M. J. Rutten, J. Boldingh, E. Schuit, H. Trum, W. Van-driel et al., Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology 25 Group study, Gynecol Oncol. déc, vol.143, issue.3, pp.511-516, 2016.

, Development and internal validation of a prognostic model for survival after debulking 28 surgery for epithelial ovarian cancer, Gynecol Oncol, vol.135, issue.1, pp.13-21, 2014.

H. Mahdi, K. A. Maurer, B. Nutter, and P. G. Rose, The Impact of Percent Reduction in CA

, Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and 2 endometrioid ovarian carcinomas, Cancer Res. 15 mars, vol.65, issue.6, pp.2162-2171, 2005.

A. Chudecka-g?az, A. Cymbaluk-p?oska, M. W??owska, and J. Menkiszak, Could HE4 level 4 measurements during first-line chemotherapy predict response to treatment among ovarian 5 cancer patients?, PLoS ONE, vol.13, issue.3, p.194270, 2018.

C. Yuan, R. Li, S. Yan, and B. Kong, Prognostic value of HE4 in patients with ovarian 7 cancer, Clin Chem Lab Med. 27 juin, vol.56, issue.7, pp.1026-1060, 2018.

N. Biglia, P. Sgandurra, V. E. Bounous, F. Maggiorotto, E. Piva et al., Ovarian 9 cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and 10 survival, Ecancermedicalscience, vol.10, p.639, 2016.

J. R. Mclaughlin, B. Rosen, J. Moody, T. Pal, F. I. Shaw et al., Long-term ovarian 12 cancer survival associated with mutation in BRCA1 or BRCA2, J Natl Cancer Inst. 16 janv, vol.13, issue.2, p.15, 2013.

S. N. Aleksakhina, High response rates to neoadjuvant platinum-based therapy in ovarian 16 cancer patients carrying germ-line BRCA mutation, Cancer Lett. 28 déc, vol.369, issue.2, pp.363-370, 2015.

M. Mendiola, A. Redondo, V. Heredia-soto, J. Herranz, A. Berjón et al.,

, Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian 19

, Carcinoma by Angiogenesis-related Genes, Anticancer Res. sept, vol.38, issue.9, pp.5393-400, 2018.